Consolidated net profit of the drug maker jumped 55 percent year-on-year to Rs 630 crore during the quarter led by growth in formulations, US and domestic businesses, and also due to higher other income and lower tax cost.
first published: Oct 28, 2014 02:55 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell
Will Nifty Bulls March Towards Fresh Peak Despite Dismal Global Cues? | Opening Bell Live
Nifty Aims For Next 26,100 After Hitting 3-Week High |Opening Bell Live
Nifty Back Above 26,000 As IT Stocks Sprint Ahead; Nvidia Earnings In Focus| Closing Bell Live
